BSE: EMMESSA · Commodity Chemicals
Limited coverage
We are not actively covering this company or have limited coverage today. Click to request coverage.
Snapshot
Growth · Profitability · Valuation · Strength · Conviction
Emmessar Biotech and Nutrition Limited is an Indian entity focused on the research, development, and marketing of healthcare products, nutritional supplements, and specialized pharmaceutical formulations. The company operates a manufacturing facility in Taloja, Maharashtra, integrating traditional healthcare concepts with modern biotechnology.
The company generates revenue by developing and marketing cost-effective healthcare solutions, skin care treatments, and nutritional additives for the domestic Indian market. It leverages its manufacturing capabilities in fine chemicals and pharmaceutical formulations to serve niche segments.
Growth is driven by the company's focus on expanding its niche presence in the Indian healthcare and biotechnology sectors. The firm aims to leverage its existing manufacturing infrastructure to scale the production of specialized pharmaceutical and nutritional products.
Unlock AI insights, financials, peers and live data on Emmessar Biotech & Nutrition Ltd. and 5,000+ companies — free.
REVENUE
₹0.37 Cr
TTM · standalone
NET PROFIT
₹0.47 Cr
TTM · standalone
EPS
₹0.96
TTM · standalone
RETURN ON EQUITY
6.0%
TTM · standalone
RETURN ON CAPITAL EMPLOYED
8.6%
TTM · standalone
P/E
23.9x
Q3 FY26 · standalone
EV/EBITDA
13.8x
Q3 FY26 · standalone
EBITDA MARGIN
232.4%
TTM · standalone
NET PROFIT MARGIN
133.3%
Q3 FY26 · standalone
DEBT TO EQUITY
0.0x
Q4 FY26 · standalone
| Company | Mkt Cap | P/E | EV/EBITDA | Rev Gr YoY | EBITDA Mgn | ROE | ROCE | 1Y Return |
|---|---|---|---|---|---|---|---|---|
Emmessar Biotech & Nutrition Ltd.EMMESSA | ₹12 Cr | 23.95 | 13.80 | -38.3% | 232.4% | 6.0% | 8.6% | -30.1% |
POCL EnterprisesPOEL | ₹432 Cr | 11.28 | 8.00 | — | 4.5% | 18.7% | 30.1% | -40.8% |
Blue Pearl Agriventures LimitedBPAGRI | ₹410 Cr | — | — | — | 2.7% | — | — | -93.2% |
Lords Chloro Alkali LimitedLORDSCHLO | ₹394 Cr | 11.41 | 7.79 | 29.8% | 17.3% | 15.6% | 14.1% | -20.6% |
Mangalam OrganicMANORG | ₹392 Cr | 18.31 | 8.38 | 17.3% | 13.6% | 6.8% | 15.9% | -18.6% |
Genus Prime Infra LimitedGENUSPRIME | ₹280 Cr | 7.11 | 36.14 | 543.4% | 181.2% | 4.7% | 4.8% | +15.0% |
As of Q3 FY26
Emmessar Biotech & Nutrition Ltd.
BSE: EMMESSA · Commodity Chemicals
Limited coverage
We are not actively covering this company or have limited coverage today. Click to request coverage.
Snapshot
Growth · Profitability · Valuation · Strength · Conviction
Emmessar Biotech and Nutrition Limited is an Indian entity focused on the research, development, and marketing of healthcare products, nutritional supplements, and specialized pharmaceutical formulations. The company operates a manufacturing facility in Taloja, Maharashtra, integrating traditional healthcare concepts with modern biotechnology.
The company generates revenue by developing and marketing cost-effective healthcare solutions, skin care treatments, and nutritional additives for the domestic Indian market. It leverages its manufacturing capabilities in fine chemicals and pharmaceutical formulations to serve niche segments.
Growth is driven by the company's focus on expanding its niche presence in the Indian healthcare and biotechnology sectors. The firm aims to leverage its existing manufacturing infrastructure to scale the production of specialized pharmaceutical and nutritional products.
Unlock AI insights, financials, peers and live data on Emmessar Biotech & Nutrition Ltd. and 5,000+ companies — free.
REVENUE
₹0.37 Cr
TTM · standalone
NET PROFIT
₹0.47 Cr
TTM · standalone
EPS
₹0.96
TTM · standalone
RETURN ON EQUITY
6.0%
TTM · standalone
RETURN ON CAPITAL EMPLOYED
8.6%
TTM · standalone
P/E
23.9x
Q3 FY26 · standalone
EV/EBITDA
13.8x
Q3 FY26 · standalone
EBITDA MARGIN
232.4%
TTM · standalone
NET PROFIT MARGIN
133.3%
Q3 FY26 · standalone
DEBT TO EQUITY
0.0x
Q4 FY26 · standalone
As of Q3 FY26